A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia

Strickland, Stephen A.; Wang, Xin Victoria; Černý, Jan; Rowe, Jacob M.; Rybka, Witold B.; Tallman, Martin S.; Litzow, Mark R.; Lazarus, Hillard M.

doi:10.1080/10428194.2020.1762878

Cited by 5 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…42 Even though EP is tolerable in AML patients, evidence concerning its efficacy remains ambiguous. [42][43][44][45][46] EP proved to have a favorable safety profile in AML patients to doses up to 300 mg. 43 Additionally, although EP inhibits breast cancer resistance protein (BCRP), which is a substrate for daunorubicin, thus implementing increased risk for cardiotoxicity, a study denoted no cardiotoxic effects in patients receiving both EP and daunorubicin; yet, EP's efficacy was not demonstrated. 42 A recent study in patients receiving induction chemotherapy reported that although EP addition led to significant decrease in platelet transfusions, it did not affect survival.…”

Section: Thrombopoietin Receptor Agonists In Acute Myeloid Leukemiamentioning

confidence: 99%

“…25 Moreover, Mukherjee et al reported that EP hastened platelet response rates and reduced transfusions during induction chemotherapy, which is in accordance with findings from a study of EP during consolidation chemotherapy. 45,46 Data regarding ROMI's use are scarce, since AML patients present with elevated TPO levels that may prevent ROMI's action. [2][3][4] Besides EP's newly emerged antileukemic properties, TPO-RAs are promising candidates for treating thrombocytopenic AML patients.…”

Section: Thrombopoietin Receptor Agonists In Acute Myeloid Leukemiamentioning

confidence: 99%

See 1 more Smart Citation

Novel Perspectives on Thrombopoietin Receptor Agonists Applications

Stafylidis,

Vlachopoulou,

Syriopoulou

et al. 2024

Hamostaseologie

View full text Add to dashboard Cite

Second-generation thrombopoietin receptor agonists (TPO-RAs), romiplostim, eltrombopag, and avatrombopag, have been proved to be significant stimulators of megakaryopoiesis and, in the last decade, they have been incorporated in the treatment options against refractory immune thrombocytopenia in children and adults that do not respond to conventional therapy. Additionally, given their beneficial impact on hematopoiesis, they have successfully been applied in cases of non-immune thrombocytopenia, such as aplastic anemia, HCV-related thrombocytopenia, chronic liver disease, and most recently acute radiation syndrome. During the past years, a wide variety of clinical studies have been performed, in regard to the use of TPO-RAs in various thrombocytopenic settings, such as malignant hematology and hematopoietic stem cell transplantation, hereditary thrombocytopenias, and chemotherapy-treated patients with solid organ tumors. Although data indicate that TPO-RAs may be an effective and safe option for managing disease- or treatment-related thrombocytopenia in these patients, further research is needed to determine their efficacy and safety in these settings. Furthermore, recent studies have highlighted novel properties of TPO-RAs that render them as potential treatment candidates for reducing tumor burden or fighting infections. Herein, we discuss the potential novel applications of TPO-RAs and focus on data regarding their efficacy and safety in these contexts.

show abstract